Los Angeles Capital Management & Equity Research Inc. Acquires New Position in Sage Therapeutics, Inc. (SAGE)

Los Angeles Capital Management & Equity Research Inc. acquired a new position in Sage Therapeutics, Inc. (NASDAQ:SAGE) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 3,450 shares of the biopharmaceutical company’s stock, valued at approximately $215,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Sage Therapeutics by 11.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 138 shares during the period. Hershey Trust Co. bought a new position in Sage Therapeutics during the third quarter valued at approximately $118,000. Turner Investments LLC bought a new position in Sage Therapeutics during the second quarter valued at approximately $159,000. Canada Pension Plan Investment Board bought a new position in Sage Therapeutics during the second quarter valued at approximately $175,000. Finally, Bessemer Group Inc. bought a new position in Sage Therapeutics during the third quarter valued at approximately $141,000. 95.40% of the stock is owned by hedge funds and other institutional investors.

Shares of Sage Therapeutics, Inc. (NASDAQ SAGE) opened at $92.66 on Tuesday. Sage Therapeutics, Inc. has a 52-week low of $44.55 and a 52-week high of $100.50.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.98) by $0.01. The firm’s revenue for the quarter was up .0% on a year-over-year basis. equities research analysts expect that Sage Therapeutics, Inc. will post -7.38 EPS for the current year.

A number of brokerages recently commented on SAGE. Royal Bank Of Canada dropped their price target on Sage Therapeutics from $145.00 to $137.00 and set an “outperform” rating for the company in a research note on Monday, November 27th. BMO Capital Markets reissued an “outperform” rating and set a $112.00 price target (up from $85.67) on shares of Sage Therapeutics in a research note on Friday, November 17th. Bank of America dropped their price target on Sage Therapeutics from $103.00 to $101.00 and set a “buy” rating for the company in a research note on Thursday, November 16th. SunTrust Banks increased their price target on Sage Therapeutics to $116.00 and gave the company a “positive” rating in a research note on Wednesday, November 15th. Finally, Needham & Company LLC increased their price target on Sage Therapeutics from $86.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, November 10th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $105.14.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/12/05/los-angeles-capital-management-equity-research-inc-acquires-new-position-in-sage-therapeutics-inc-sage.html.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

What are top analysts saying about Sage Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sage Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit